Erectile Dysfunction and Lower Urinary Tract Symptoms
- 97 Downloads
Purpose of Review
In the past years, the relationship between lower urinary tract symptoms and erectile dysfunction has been widely explored. The aim of our systematic review is to summarize the published evidence over the past year on lower urinary tract symptoms (LUTS) and erectile dysfunction (ED).
Recent data support the relationship between LUTS and ED in Eastern Europe and in Asia. The role of phosphodiesterase inhibitors alone or in combination with alpha blockers to treat LUTS and ED, especially in younger patients, is strongly supported by high level of evidence.
LUTS and ED are prevalent conditions in men over 50; epidemiologically, the relationship between both conditions has been confirmed all over the world. PDE5i alone or in combination with alpha blockers can be considered the gold standard for the treatment of young patients with storage symptoms and concomitant ED. In clinical research, a better understanding of the molecular pathways behind this association may also help to identify new possible targets and develop novel therapeutic approaches to manage both disorders; the identification of new biomarkers of both disorders is also compulsory in this area.
KeywordsProstate LUTS Erectile dysfunction Diagnosis Outcome Treatment
Compliance with Ethical Standards
Conflict of Interest
Cosimo De Nunzio, Riccardo Lombardo, Giorgia Tema, and Andrea Tubaro each declares no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 9.Tibaek S, Gard G, Dehlendorff C, et al. Lower urinary tract symptoms, erectile dysfunction, and quality of life in poststroke men. Am J Mens Health. 2017; https://doi.org/10.1177/1557988317690283.
- 10.Calogero AE, Burgio G, Condorelli RA, et al. Lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction: from physiology to clinical aspects. Aging Male. 2018:1–10.Google Scholar
- 20.•• Oelke M, Wagg A, Takita Y, Büttner H, Viktrup L. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled cli. BJU Int. 2017;119:793–803. Pooled analysis on efficacy of tadalafil of randomised clinical trials summarizes efficacy of tadalafil 5 mg. CrossRefPubMedGoogle Scholar
- 21.Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, et al. Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafil for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial. J Sex Med. 2017;14:1018–27.CrossRefPubMedGoogle Scholar
- 23.Matsukawa Y, Majima T, Matsuo K, Funahashi Y, Kato M, Yamamoto T, et al. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a urodynamic-based study. Int J Urol. 2018;25:246–50.CrossRefPubMedGoogle Scholar
- 26.Ko WJ, Han HH, Ham WS, Lee HW. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male. 2017;20:81–8.CrossRefPubMedGoogle Scholar
- 28.Sokhal AK, Sankhwar S, Goel A, Singh K, Kumar M, Purkait B, et al. A prospective study to evaluate sexual dysfunction and enlargement of seminal vesicles in sexually active men treated for benign prostatic hyperplasia by alpha blockers. Urology. 2017; https://doi.org/10.1016/j.urology.2017.08.025.
- 29.Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30 https://doi.org/10.1515/hmbci-2017-0015.
- 30.• Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC, et al. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018;121:647–58. Important level 1 evidence on side effects of combination therapy. CrossRefPubMedGoogle Scholar